Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of scutellarin in preparation of medicine for preventing and treating atherosclerosis

A technology for atherosclerosis and scutellarin, which is applied in the fields of biomedicine and medicine, can solve the problem that the mechanism of scutellarin against AS is not clear, and achieve the effect of lowering blood lipid levels

Inactive Publication Date: 2021-04-06
DALIAN MEDICAL UNIVERSITY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In previous studies, we found that in the NALFD mouse model, scutellarin can up-regulate Nrf2 to exert hepatoprotective and antioxidant effects. Some studies have used scutellarin for the treatment of other diseases and found corresponding treatments effect, but the mechanism of scutellarin against AS has not yet been clarified

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of scutellarin in preparation of medicine for preventing and treating atherosclerosis
  • Application of scutellarin in preparation of medicine for preventing and treating atherosclerosis
  • Application of scutellarin in preparation of medicine for preventing and treating atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 The effect of scutellarin (Scu) on AS by regulating the PERK-Nrf2 / ATF4-CHOP pathway

[0043] 1. Animal AS model establishment and processing

[0044] Forty healthy male SD rats were randomly divided into 4 groups, with 10 rats in each group. They were respectively set as: (A) blank control group; (B) model group; (C) scutellarin low-dose group; (D) scutellarin high-dose group. The feeding and administration methods of each group are shown in Table 1. Show. SD rats were administered daily and weighed once a week during feeding, and model establishment was terminated after continuous feeding for 12w. After fasting for 12 hours, SD rats were anesthetized with 10% chloral hydrate, and the abdominal aortic blood was taken out into EP tubes, and after standing for 4 hours, centrifuged at 3000 rpm at 4°C for 10 minutes, the supernatant was taken and stored in a -80°C refrigerator .

[0045] Table 1 Each group of animal feeding and administration methods

[0046]...

Embodiment 2

[0091] Example 2 Protective effect of scutellarin on HAECs cell damage induced by 2,2-azobis(2-methylpropylimidium) dihydrochloride (AAPH)

[0092] 1. Culture of human aortic endothelial cells (HAECs)

[0093] Take out the cell cryopreservation tube and quickly dissolve it in a 37°C water bath. Add an appropriate amount of cell culture medium to the centrifuge tube in advance, transfer the liquid in the cryopreservation tube into the prepared centrifuge tube in a sterile ultra-clean bench, blow and beat evenly, and centrifuge at 1000g for 5min. Keep only the precipitate, add 2mL of cell culture medium to pipette the precipitate into a cell suspension. Transfer the cell suspension into a culture flask, and add 1 mL of cell culture medium. Place at 37°C with 5% CO 2 Cultured in an incubator, and the medium was changed the next day.

[0094] When the cells basically covered the bottom of the bottle, they were digested and subcultured with 0.25% trypsin (containing 0.02% EDTA)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of scutellarin in preparation of a medicine for preventing and treating atherosclerosis, which belongs to the field of biomedicine and medicines, and discloses an application of scutellarin in preparation of a medicine for preventing and treating atherosclerosis related to a PERK-Nrf2 / ATF4-CHOP pathway. The scutellarin is used as a PERK-Nrf2 / ATF4-CHOP signal path regulating agent for preventing and treating atherosclerosis. The scutellarin disclosed by the invention can be used for preventing and treating atherosclerosis by resisting endoplasmic reticulum stress and endothelial cell apoptosis, has important significance for clinical treatment of atherosclerosis, and can be used for developing related medicines.

Description

technical field [0001] The invention relates to the fields of biomedicine and medicine, in particular to the application of scutellarin in the preparation of drugs for preventing and treating atherosclerosis. Background technique [0002] Atherosclerosis (AS) is a complex arterial disease characterized by vessel wall inflammation and AS plaque accumulation. Statistics from the World Health Organization show that AS has become one of the most common causes of death worldwide. The pathogenesis of AS has been a research hotspot in the past few decades. However, due to the many causes and complex pathophysiological processes, there is no unified conclusion on the pathogenesis of AS. However, there is still an urgent need for effective drugs and strategies to treat AS in clinical practice. . [0003] Endothelial cells (EC) are the first barrier between tissues and blood, and play an important role in hemostasis, hormone transport, signal transduction and inflammation. A variety...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P9/10
CPCA61K31/7048A61P9/10
Inventor 金越孙慧君吕莉赵艳艳邹林沙珊珊唐晓
Owner DALIAN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com